Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 2
1984 3
1985 16
1986 5
1987 6
1988 5
1989 10
1990 8
1991 15
1992 10
1993 3
1994 4
1995 3
1996 3
1997 1
1998 1
1999 1
2000 2
2001 3
2002 1
2003 2
2005 2
2006 3
2007 1
2008 4
2009 3
2010 6
2011 4
2012 5
2013 4
2014 5
2015 2
2016 5
2017 4
2018 4
2019 4
2020 3
2021 2
2022 2
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

168 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET).
Overcash JS, Kim C, Keech R, Gumenchuk I, Ninov B, Gonzalez-Rojas Y, Waters M, Simeonov S, Engelhardt M, Saulay M, Ionescu D, Smart JI, Jones ME, Hamed KA. Overcash JS, et al. Clin Infect Dis. 2021 Oct 5;73(7):e1507-e1517. doi: 10.1093/cid/ciaa974. Clin Infect Dis. 2021. PMID: 32897367 Free PMC article. Clinical Trial.
Noninferiority was defined as the lower limit of the 95% CI for the difference in success rates (ceftobiprole minus vancomycin/aztreonam) >-10%. Safety was assessed through adverse event and laboratory data collection. RESULTS: In total, 679 patients were randomized to …
Noninferiority was defined as the lower limit of the 95% CI for the difference in success rates (ceftobiprole minus vancomycin/aztreonam
Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia.
Holland TL, Cosgrove SE, Doernberg SB, Jenkins TC, Turner NA, Boucher HW, Pavlov O, Titov I, Kosulnykov S, Atanasov B, Poromanski I, Makhviladze M, Anderzhanova A, Stryjewski ME, Assadi Gehr M, Engelhardt M, Hamed K, Ionescu D, Jones M, Saulay M, Smart J, Seifert H, Fowler VG Jr; ERADICATE Study Group. Holland TL, et al. N Engl J Med. 2023 Oct 12;389(15):1390-1401. doi: 10.1056/NEJMoa2300220. Epub 2023 Sep 27. N Engl J Med. 2023. PMID: 37754204 Free article. Clinical Trial.
METHODS: In this phase 3, double-blind, double-dummy, noninferiority trial, adults with complicated S. aureus bacteremia were randomly assigned in a 1:1 ratio to receive ceftobiprole at a dose of 500 mg intravenously every 6 hours for 8 days and every 8 hours thereafter, or dapto …
METHODS: In this phase 3, double-blind, double-dummy, noninferiority trial, adults with complicated S. aureus bacteremia were randomly assig …
Aztreonam for Neisseria gonorrhoeae: a systematic review and meta-analysis.
Barbee LA, Golden MR. Barbee LA, et al. J Antimicrob Chemother. 2020 Jul 1;75(7):1685-1688. doi: 10.1093/jac/dkaa108. J Antimicrob Chemother. 2020. PMID: 32259846 Free PMC article.
METHODS: We conducted a literature review of clinical trials and case series, published from 1983 to 2017, reporting treatment efficacy results following administration of 1 g aztreonam intramuscularly or IV for uncomplicated gonococcal infections. ...CONCLUSIONS: Although …
METHODS: We conducted a literature review of clinical trials and case series, published from 1983 to 2017, reporting treatment efficacy resu …
Ceftazidime-avibactam and aztreonam combination for Carbapenem-resistant Enterobacterales bloodstream infections with presumed Metallo-beta-lactamase production: a systematic review and meta-analysis.
Gupta N, Boodman C, Prayag P, Manesh A, Kumar TP. Gupta N, et al. Expert Rev Anti Infect Ther. 2024 Apr;22(4):203-209. doi: 10.1080/14787210.2024.2307912. Epub 2024 Feb 8. Expert Rev Anti Infect Ther. 2024. PMID: 38258529 Review.
INTRODUCTION: Carbapenem-resistant Enterobacterales (CRE) due to Metallo-beta-lactamase (MBL) production are treated with either polymyxins or the novel combination of ceftazidime-avibactam and aztreonam (AA). This study aims to evaluate the 30-day mortality of AA in patie …
INTRODUCTION: Carbapenem-resistant Enterobacterales (CRE) due to Metallo-beta-lactamase (MBL) production are treated with either polymyxins …
Klebsiella pneumoniae: an increasing threat to public health.
Effah CY, Sun T, Liu S, Wu Y. Effah CY, et al. Ann Clin Microbiol Antimicrob. 2020 Jan 9;19(1):1. doi: 10.1186/s12941-019-0343-8. Ann Clin Microbiol Antimicrob. 2020. PMID: 31918737 Free PMC article. Review.
RESULTS: The prevalence rate of drug resistance in K. pneumoniae were; amikacin (40.8%) [95% CI 31.9-50.4], aztreonam (73.3%) [95% CI 59.9-83.4], ceftazidime (75.7%) [95% CI 65.4-83.6], ciprofloxacin (59.8%) [95% CI 48.6-70.1], colistin (2.9%) [95% CI 1.8-4.4], cefotaxime …
RESULTS: The prevalence rate of drug resistance in K. pneumoniae were; amikacin (40.8%) [95% CI 31.9-50.4], aztreonam (73.3%) [95% CI …
Preservation of colonization resistance parameters during empiric therapy with aztreonam in the febrile neutropenic patient.
Louie TJ, Chubb H, Bow EJ, Conly JM, Harding GK, Rayner E, James M. Louie TJ, et al. Rev Infect Dis. 1985 Nov-Dec;7 Suppl 4:S747-61. doi: 10.1093/clinids/7.supplement_4.s747. Rev Infect Dis. 1985. PMID: 3909333 Review.
Fungi were acquired at 11 (22%) of 49 sites in aztreonam/tobramycin, 15 (31%) of 48 sites in aztreonam/cloxacillin, and 28 (54%) of 52 sites in moxalactam/tobramycin recipients. Aztreonam/tobramycin reduced fecal anaerobe counts by less than 1 log10; aztre
Fungi were acquired at 11 (22%) of 49 sites in aztreonam/tobramycin, 15 (31%) of 48 sites in aztreonam/cloxacillin, and 28 (54 …
Aztreonam compared with gentamicin for treatment of serious urinary tract infections.
Sattler FR, Moyer JE, Schramm M, Lombard JS, Appelbaum PC. Sattler FR, et al. Lancet. 1984 Jun 16;1(8390):1315-8. doi: 10.1016/s0140-6736(84)91817-8. Lancet. 1984. PMID: 6145024 Clinical Trial.
52 patients with serious urinary tract infections were randomised to receive either aztreonam (35) or gentamicin (17). In the aztreonam group 23 patients had unqualified cures, 6 cures with relapse, and 6 cures with reinfection; the comparable numbers in the gentami …
52 patients with serious urinary tract infections were randomised to receive either aztreonam (35) or gentamicin (17). In the aztr
Cross-allergenicity and immunogenicity of aztreonam.
Adkinson NF Jr, Saxon A, Spence MR, Swabb EA. Adkinson NF Jr, et al. Rev Infect Dis. 1985 Nov-Dec;7 Suppl 4:S613-21. doi: 10.1093/clinids/7.supplement_4.s613. Rev Infect Dis. 1985. PMID: 4081473 Clinical Trial.
Rabbit antibodies to aztreonam and naturally occurring human antibodies that recognize aztreonam were found to have negligible cross-reactivity with benzylpenicillin, cephalothin, and cefotaxime. ...Only two of seven patients with preexisting IgG antibodies to az
Rabbit antibodies to aztreonam and naturally occurring human antibodies that recognize aztreonam were found to have negligible …
Effectiveness of aztreonam for the treatment of gonorrhea.
Gottlieb A, Mills J. Gottlieb A, et al. Antimicrob Agents Chemother. 1985 Feb;27(2):270-1. doi: 10.1128/AAC.27.2.270. Antimicrob Agents Chemother. 1985. PMID: 3157346 Free PMC article. Clinical Trial.
Aztreonam, 1 g intramuscularly, was compared with spectinomycin, 2 g intramuscularly, for uncomplicated gonorrhea. There were no failures with either drug. For aztreonam, there were 26 urethral, 3 rectal, and 3 endocervical sites that were infected. ...
Aztreonam, 1 g intramuscularly, was compared with spectinomycin, 2 g intramuscularly, for uncomplicated gonorrhea. There were no fail
Aztreonam versus gentamicin, each with clindamycin, in the treatment of endometritis.
Gibbs RS, Blanco JD, Lipscomb KA, St Clair PJ. Gibbs RS, et al. Obstet Gynecol. 1985 Jun;65(6):825-9. Obstet Gynecol. 1985. PMID: 3889748 Clinical Trial.
The failures in the aztreonam group were associated with a wound abscess and with an enterococcal bacteremia. ...No patient showed nephrotoxicity. When used in combination with clindamycin, aztreonam gave clinical results similar to gentamicin....
The failures in the aztreonam group were associated with a wound abscess and with an enterococcal bacteremia. ...No patient showed ne …
168 results